TY - JOUR
T1 - Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer
AU - Pothacharoen, Peraphan
AU - Siriaunkgul, Sumalee
AU - Ong-Chai, Siriwan
AU - Supabandhu, Jitwadee
AU - Kumja, Prayoon
AU - Wanaphirak, Chanane
AU - Sugahara, Kazuyuki
AU - Hardingham, Timothy
AU - Kongtawelert, Prachya
PY - 2006/10
Y1 - 2006/10
N2 - Objective: To determine the value of serum chondroitin sulfate epitope WF6 and hyaluronan (HA) levels as a biomarker for early detection of ovarian epithelial cancer and other gynecological disorders. Method: Serum WF6 CS epitope and HA were measured in 91 patients with ovarian epithelial cancer, 39 patients with non-cancer gynecological disorders and 30 healthy women. Serum chondroitin sulfate (CS) WF6 epitope was determined by a competitive immunoassay with the monoclonal antibodies WF6, which specifically recognizes an epitope in native CS chains. In addition, serum HA concentration was measured by an ELISA-based assay with a biotinylated affinity HA-binding proteins. Results: The serum concentration of CS (WF6) epitope was highly increased in epithelial types of ovarian cancer and at all stages of development (p <0.005). Serum HA in ovarian cancer patients was significantly higher than normal controls (p <0.05). Conclusion: These results reflect changes in ECM metabolism in progressive ovarian cancer, which cause an increase in serum CS epitopes and HA. Therefore, serum CS epitopes may provide useful biomarkers for cancers and other disorders of the ovary. Measurement of serum HA provided complementary information, which may be useful as a discriminator between benign ovarian disorders and malignant ovarian diseases. © 2006 The Japanese Biochemical Society.
AB - Objective: To determine the value of serum chondroitin sulfate epitope WF6 and hyaluronan (HA) levels as a biomarker for early detection of ovarian epithelial cancer and other gynecological disorders. Method: Serum WF6 CS epitope and HA were measured in 91 patients with ovarian epithelial cancer, 39 patients with non-cancer gynecological disorders and 30 healthy women. Serum chondroitin sulfate (CS) WF6 epitope was determined by a competitive immunoassay with the monoclonal antibodies WF6, which specifically recognizes an epitope in native CS chains. In addition, serum HA concentration was measured by an ELISA-based assay with a biotinylated affinity HA-binding proteins. Results: The serum concentration of CS (WF6) epitope was highly increased in epithelial types of ovarian cancer and at all stages of development (p <0.005). Serum HA in ovarian cancer patients was significantly higher than normal controls (p <0.05). Conclusion: These results reflect changes in ECM metabolism in progressive ovarian cancer, which cause an increase in serum CS epitopes and HA. Therefore, serum CS epitopes may provide useful biomarkers for cancers and other disorders of the ovary. Measurement of serum HA provided complementary information, which may be useful as a discriminator between benign ovarian disorders and malignant ovarian diseases. © 2006 The Japanese Biochemical Society.
KW - Chondroitin sulfate epitopes
KW - Hyaluronan
KW - Ovarian epithelial cancer
KW - Serum biomarker
U2 - 10.1093/jb/mvj181
DO - 10.1093/jb/mvj181
M3 - Article
C2 - 16936295
VL - 140
SP - 517
EP - 524
JO - Journal of Biochemistry
JF - Journal of Biochemistry
IS - 4
ER -